Series 7: The Last Mile of Brain Science
SERIES 7: THE LAST MILE OF BRAIN SCIENCE AUTHOR: KJ Lavan We Are Democratizing Detection Before Democratizing Care The next crisis in #Alzheimer’s disease may not be a shortage of scientific breakthroughs. It may be a shortage of systems capable of using them. The science is advancing rapidly. Lecanemab and donanemab can slow progression in appropriately selected people with early Alzheimer’s disease. But these therapies require confirmation of amyloid pathology, specialist evaluation, infusions, MRI monitoring and management of amyloid-related imaging abnormalities. ( U.S. Food and Drug Administration ) In July 2026, the FDA approved an at-home starting dose of lecanemab—another step toward making treatment more accessible. Yet, moving administration closer to the home does not eliminate the need for diagnosis, patient selection, safety surveillance and coordinated clinical oversight. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheim...